Allergy Disease R&D Company Lycia Therapeutics Expands Fundraising Scale and Is Set to List on Nasdaq
Multiple Negative Factors Hit the US Tech Sector, and Retail Investors Shift Their Focus to a Broader Range of Tech Stocks